CN106511984A - 一种用于偏头疼的药物及其制备方法 - Google Patents
一种用于偏头疼的药物及其制备方法 Download PDFInfo
- Publication number
- CN106511984A CN106511984A CN201611093827.7A CN201611093827A CN106511984A CN 106511984 A CN106511984 A CN 106511984A CN 201611093827 A CN201611093827 A CN 201611093827A CN 106511984 A CN106511984 A CN 106511984A
- Authority
- CN
- China
- Prior art keywords
- parts
- starch
- medicine
- powder
- compound vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000019695 Migraine disease Diseases 0.000 title claims abstract description 29
- 206010027599 migraine Diseases 0.000 title claims abstract description 29
- 239000003814 drug Substances 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 229940079593 drug Drugs 0.000 title 1
- 229920002472 Starch Polymers 0.000 claims abstract description 38
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims abstract description 38
- 235000019698 starch Nutrition 0.000 claims abstract description 38
- 239000008107 starch Substances 0.000 claims abstract description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 26
- 229940114930 potassium stearate Drugs 0.000 claims abstract description 26
- ANBFRLKBEIFNQU-UHFFFAOYSA-M potassium;octadecanoate Chemical compound [K+].CCCCCCCCCCCCCCCCCC([O-])=O ANBFRLKBEIFNQU-UHFFFAOYSA-M 0.000 claims abstract description 26
- 102000004190 Enzymes Human genes 0.000 claims abstract description 25
- 108090000790 Enzymes Proteins 0.000 claims abstract description 25
- 241000361919 Metaphire sieboldi Species 0.000 claims abstract description 25
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims abstract description 19
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229960001948 caffeine Drugs 0.000 claims abstract description 19
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229960002715 nicotine Drugs 0.000 claims abstract description 19
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims abstract description 19
- 150000001413 amino acids Chemical class 0.000 claims abstract description 17
- 230000003480 fibrinolytic effect Effects 0.000 claims abstract description 13
- JMFSHKGXVSAJFY-UHFFFAOYSA-N Saponaretin Natural products OCC(O)C1OC(Oc2c(O)cc(O)c3C(=O)C=C(Oc23)c4ccc(O)cc4)C(O)C1O JMFSHKGXVSAJFY-UHFFFAOYSA-N 0.000 claims abstract description 12
- MOZJVOCOKZLBQB-UHFFFAOYSA-N Vitexin Natural products OCC1OC(Oc2c(O)c(O)cc3C(=O)C=C(Oc23)c4ccc(O)cc4)C(O)C(O)C1O MOZJVOCOKZLBQB-UHFFFAOYSA-N 0.000 claims abstract description 12
- SGEWCQFRYRRZDC-VPRICQMDSA-N vitexin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(O)C2=C1OC(C=1C=CC(O)=CC=1)=CC2=O SGEWCQFRYRRZDC-VPRICQMDSA-N 0.000 claims abstract description 12
- PZKISQRTNNHUGF-UHFFFAOYSA-N vitexine Natural products OC1C(O)C(O)C(CO)OC1OC1=C(O)C=C(O)C2=C1OC(C=1C=CC(O)=CC=1)=CC2=O PZKISQRTNNHUGF-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 239000000843 powder Substances 0.000 claims description 43
- 235000013343 vitamin Nutrition 0.000 claims description 38
- 229940088594 vitamin Drugs 0.000 claims description 38
- 229930003231 vitamin Natural products 0.000 claims description 38
- 239000011782 vitamin Substances 0.000 claims description 38
- -1 compound vitamin Chemical class 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 25
- 229940024606 amino acid Drugs 0.000 claims description 16
- 235000001014 amino acid Nutrition 0.000 claims description 16
- LNSXRXFBSDRILE-UHFFFAOYSA-N Cucurbitacin Natural products CC(=O)OC(C)(C)C=CC(=O)C(C)(O)C1C(O)CC2(C)C3CC=C4C(C)(C)C(O)C(O)CC4(C)C3(C)C(=O)CC12C LNSXRXFBSDRILE-UHFFFAOYSA-N 0.000 claims description 13
- CVKKIVYBGGDJCR-SXDZHWHFSA-N Cucurbitacin B Natural products CC(=O)OC(C)(C)C=CC(=O)[C@@](C)(O)[C@@H]1[C@@H](O)C[C@]2(C)C3=CC[C@@H]4C(C)(C)C(=O)[C@H](O)C[C@@]4(C)[C@@H]3CC(=O)[C@@]12C CVKKIVYBGGDJCR-SXDZHWHFSA-N 0.000 claims description 13
- PIGAXYFCLPQWOD-UHFFFAOYSA-N dihydrocucurbitacin I Natural products CC12C(=O)CC3(C)C(C(C)(O)C(=O)CCC(C)(O)C)C(O)CC3(C)C1CC=C1C2C=C(O)C(=O)C1(C)C PIGAXYFCLPQWOD-UHFFFAOYSA-N 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 13
- 150000001904 cucurbitacins Chemical class 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 12
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 5
- 239000004472 Lysine Substances 0.000 claims description 5
- 240000001085 Trapa natans Species 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 235000009165 saligot Nutrition 0.000 claims description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 4
- 244000017020 Ipomoea batatas Species 0.000 claims description 4
- 235000002678 Ipomoea batatas Nutrition 0.000 claims description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 4
- 229920001592 potato starch Polymers 0.000 claims description 4
- 229960004441 tyrosine Drugs 0.000 claims description 4
- 229920002261 Corn starch Polymers 0.000 claims description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 239000008120 corn starch Substances 0.000 claims description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 3
- 229910021529 ammonia Inorganic materials 0.000 claims description 2
- VKEQBMCRQDSRET-UHFFFAOYSA-N Methylone Chemical compound CNC(C)C(=O)C1=CC=C2OCOC2=C1 VKEQBMCRQDSRET-UHFFFAOYSA-N 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 125000001202 cucurbitacin group Chemical group 0.000 claims 1
- 229940116364 hard fat Drugs 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 4
- 238000005516 engineering process Methods 0.000 abstract description 3
- 238000009776 industrial production Methods 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- UZEAHFLEZWXHCE-UHFFFAOYSA-N 3-iodo-2-methylaniline Chemical compound CC1=C(N)C=CC=C1I UZEAHFLEZWXHCE-UHFFFAOYSA-N 0.000 abstract 2
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 19
- 206010019233 Headaches Diseases 0.000 description 9
- 231100000869 headache Toxicity 0.000 description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 230000001476 alcoholic effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- MJEMIOXXNCZZFK-UHFFFAOYSA-N ethylone Chemical compound CCNC(C)C(=O)C1=CC=C2OCOC2=C1 MJEMIOXXNCZZFK-UHFFFAOYSA-N 0.000 description 1
- 230000001709 ictal effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4806—Hydrolases (3) acting on peptide bonds (3.4) from animals other than mammals, e.g. snakes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种用于偏头疼的药物,由以下原料按照重量份组成:葫芦素2‑5份、牡荆素0.5‑3份、淀粉7‑15份、复合维生素3‑7份、乙醇溶液5‑12份、蚯蚓蛋白酶0.1‑2份、硬脂酸钾1‑6份、咖啡因8‑18份、氨基酸3‑7份和尼古丁0.1‑0.5份。本发明还公布了该药物的制备方法。本发明原料来源广泛并且原材料价格低廉,制备工艺简单,生产设备投资成本小,适用于大规模的工业化生产;本发明中复合维生素、硬脂酸钾、葫芦素等组分起协同作用,见效时间快,治疗时间短,没有毒副作用,使用效果好,市场前景广阔。
Description
技术领域
本发明涉及医药制备领域,具体是一种用于偏头疼的药物。
背景技术
随着工作和生活压力的增大,各种病症困扰着人们,偏头疼就是其中一种。偏头疼是临床最常见的原发性头痛类型,临床以发作性中重度、搏动样头痛为主要表现,头痛多为偏侧,一般持续4-72小时,可伴有恶心、呕吐,光、声刺激或日常活动均可加重头痛,安静环境、休息可缓解头痛,偏头疼频繁发作将影响患者的生活工作,最直接的就是影响睡眠,因为睡眠不足,白天就没精神,工作也大受影响。女性多发,约为男性的3-4倍,多在青春期起病,发病年龄25-34岁,少数发生于儿童期或中年后。偏头疼主要包括有先兆的偏头疼和无先兆的偏头疼两大类。目前人们采用药物治疗偏头疼都是为了减轻或者终止头疼发作,缓解并发症状,但是治疗时间长,治疗效果不理想,偏头疼仍然会反复发作,这就为人们的生活和工作带来了困扰。
发明内容
本发明的目的在于提供一种用于偏头疼的药物,以解决上述背景技术中提出的问题。
为实现上述目的,本发明提供如下技术方案:
一种用于偏头疼的药物,由以下原料按照重量份组成:葫芦素2-5份、牡荆素0.5-3份、淀粉7-15份、复合维生素3-7份、乙醇溶液5-12份、蚯蚓蛋白酶0.1-2份、硬脂酸钾1-6份、咖啡因8-18份、氨基酸3-7份和尼古丁0.1-0.5份。
作为本发明进一步的方案:氨基酸为赖氨酸、谷氨酸、色氨酸、苯丙氨酸和酪氨酸的一种或者多种的混合物,复合维生素采用甲基复合维生素、微晶复合维生素和乙基复合维生素的一种或者多种的混合物。
作为本发明进一步的方案:乙醇溶液的体积分数为40-55%,淀粉采用玉米淀粉、葛根淀粉、红薯淀粉和菱角淀粉的一种或者多种的混合物。
所述用于偏头疼的药物的制备方法,具体步骤如下:
步骤一,将硬脂酸钾、淀粉、复合维生素和蚯蚓蛋白酶分别粉碎并且过80-120目筛子,得到硬脂酸钾粉末、淀粉粉末、复合维生素粉末和蚯蚓蛋白酶粉末备用;
步骤二,将葫芦素、牡荆素、淀粉粉末、复合维生素粉末和蚯蚓蛋白酶粉末加入乙醇溶液中,搅拌机在常温下进行搅拌,边搅拌边加入咖啡因、氨基酸和尼古丁,咖啡因、氨基酸和尼古丁加入完毕后,搅拌机在常温下以150-240rpm的转速搅拌30-60分钟,搅拌结束后将混合溶液放在55-75摄氏度的干燥箱中烘干并且烘干产物过20-30目筛,得到干燥颗粒;
步骤三,将硬脂酸钾加入到干燥颗粒中并且混合均匀,然后将混合物填充到胶囊中即可得到成品。
与现有技术相比,本发明的有益效果是:本发明原料来源广泛并且原材料价格低廉,制备工艺简单,生产设备投资成本小,适用于大规模的工业化生产;本发明中复合维生素、硬脂酸钾、葫芦素等组分起协同作用,见效时间快,治疗时间短,没有毒副作用,使用效果好,市场前景广阔。
具体实施方式
下面结合具体实施方式对本专利的技术方案作进一步详细地说明。
实施例1
一种用于偏头疼的药物,由以下原料按照重量份组成:葫芦素2份、牡荆素0.5份、淀粉7份、复合维生素3份、乙醇溶液5份、蚯蚓蛋白酶0.1份、硬脂酸钾1份、咖啡因8份、氨基酸3份和尼古丁0.1份。氨基酸为赖氨酸和酪氨酸的混合物,复合维生素采用甲基复合维生素和乙基复合维生素的混合物。
所述用于偏头疼的药物的制备方法,具体步骤如下:
步骤一,将硬脂酸钾、淀粉、复合维生素和蚯蚓蛋白酶分别粉碎并且过80目筛子,得到硬脂酸钾粉末、淀粉粉末、复合维生素粉末和蚯蚓蛋白酶粉末备用;
步骤二,将葫芦素、牡荆素、淀粉粉末、复合维生素粉末和蚯蚓蛋白酶粉末加入乙醇溶液中,搅拌机在常温下进行搅拌,边搅拌边加入咖啡因、氨基酸和尼古丁,咖啡因、氨基酸和尼古丁加入完毕后,搅拌机在常温下以150rpm的转速搅拌35分钟,搅拌结束后将混合溶液放在58摄氏度的干燥箱中烘干并且烘干产物过20目筛,得到干燥颗粒;
步骤三,将硬脂酸钾加入到干燥颗粒中并且混合均匀,然后将混合物填充到胶囊中即可得到成品。
实施例2
一种用于偏头疼的药物,由以下原料按照重量份组成:葫芦素3.5份、牡荆素1.5份、淀粉9份、复合维生素5份、乙醇溶液8份、蚯蚓蛋白酶0.7份、硬脂酸钾3份、咖啡因11份、氨基酸4.5份和尼古丁0.2份。乙醇溶液的体积分数为40%,淀粉采用葛根淀粉和菱角淀粉的混合物。
所述用于偏头疼的药物的制备方法,具体步骤如下:
步骤一,将硬脂酸钾、淀粉、复合维生素和蚯蚓蛋白酶分别粉碎并且过100目筛子,得到硬脂酸钾粉末、淀粉粉末、复合维生素粉末和蚯蚓蛋白酶粉末备用;
步骤二,将葫芦素、牡荆素、淀粉粉末、复合维生素粉末和蚯蚓蛋白酶粉末加入乙醇溶液中,搅拌机在常温下进行搅拌,边搅拌边加入咖啡因、氨基酸和尼古丁,咖啡因、氨基酸和尼古丁加入完毕后,搅拌机在常温下以180rpm的转速搅拌45分钟,搅拌结束后将混合溶液放在60摄氏度的干燥箱中烘干并且烘干产物过24目筛,得到干燥颗粒;
步骤三,将硬脂酸钾加入到干燥颗粒中并且混合均匀,然后将混合物填充到胶囊中即可得到成品。
实施例3
一种用于偏头疼的药物,由以下原料按照重量份组成:葫芦素4份、牡荆素2.5份、淀粉13份、复合维生素6份、乙醇溶液10份、蚯蚓蛋白酶1.4份、硬脂酸钾5份、咖啡因15份、氨基酸5份和尼古丁0.3份。氨基酸为赖氨酸、谷氨酸和色氨酸的混合物,复合维生素采用甲基复合维生素。乙醇溶液的体积分数为48%,淀粉采用红薯淀粉和菱角淀粉的混合物。
所述用于偏头疼的药物的制备方法,具体步骤如下:
步骤一,将硬脂酸钾、淀粉、复合维生素和蚯蚓蛋白酶分别粉碎并且过110目筛子,得到硬脂酸钾粉末、淀粉粉末、复合维生素粉末和蚯蚓蛋白酶粉末备用;
步骤二,将葫芦素、牡荆素、淀粉粉末、复合维生素粉末和蚯蚓蛋白酶粉末加入乙醇溶液中,搅拌机在常温下进行搅拌,边搅拌边加入咖啡因、氨基酸和尼古丁,咖啡因、氨基酸和尼古丁加入完毕后,搅拌机在常温下以210rpm的转速搅拌54分钟,搅拌结束后将混合溶液放在70摄氏度的干燥箱中烘干并且烘干产物过28目筛,得到干燥颗粒;
步骤三,将硬脂酸钾加入到干燥颗粒中并且混合均匀,然后将混合物填充到胶囊中即可得到成品。
实施例4
一种用于偏头疼的药物,由以下原料按照重量份组成:葫芦素5份、牡荆素3份、淀粉15份、复合维生素7份、乙醇溶液12份、蚯蚓蛋白酶2份、硬脂酸钾6份、咖啡因18份、氨基酸7份和尼古丁0.5份。氨基酸为赖氨酸、谷氨酸、色氨酸、苯丙氨酸和酪氨酸的混合物,复合维生素采用甲基复合维生素、微晶复合维生素和乙基复合维生素的混合物。乙醇溶液的体积分数为55%,淀粉采用玉米淀粉、葛根淀粉、红薯淀粉和菱角淀粉的混合物。
所述用于偏头疼的药物的制备方法,具体步骤如下:
步骤一,将硬脂酸钾、淀粉、复合维生素和蚯蚓蛋白酶分别粉碎并且过120目筛子,得到硬脂酸钾粉末、淀粉粉末、复合维生素粉末和蚯蚓蛋白酶粉末备用;
步骤二,将葫芦素、牡荆素、淀粉粉末、复合维生素粉末和蚯蚓蛋白酶粉末加入乙醇溶液中,搅拌机在常温下进行搅拌,边搅拌边加入咖啡因、氨基酸和尼古丁,咖啡因、氨基酸和尼古丁加入完毕后,搅拌机在常温下以240rpm的转速搅拌50分钟,搅拌结束后将混合溶液放在75摄氏度的干燥箱中烘干并且烘干产物过30目筛,得到干燥颗粒;
步骤三,将硬脂酸钾加入到干燥颗粒中并且混合均匀,然后将混合物填充到胶囊中即可得到成品。
选择400名具有偏头疼的患者,男女各占一半,年龄在20-45岁,随机平均分成5组,每组男女各占一半。对1-4组患者分别服用实施例1-4的产品,对5组患者服用现有产品,每次1.5g并且采用温开水送服,每天3次,持续一周,一周后治疗效果见表1。治疗标准:痊愈:不再头疼,没有失眠等症状;有效:头疼症状减轻,伴随轻微的失眠等症状;无效:头疼症状没有好转甚至加重,失眠等症状没有好转甚至加重。
表1
治愈数量(人) | 有效数量(人) | 无效数量(人) | 治愈率(%) | 有效率(%) | |
1组 | 64 | 16 | 0 | 80 | 100 |
2组 | 61 | 18 | 1 | 76.25 | 98.75 |
3组 | 56 | 24 | 0 | 70 | 100 |
4组 | 55 | 23 | 2 | 68.75 | 97.5 |
5组 | 32 | 26 | 22 | 40 | 72.5 |
从表1可以看出,实施例1-4的产品的治愈率和有效率均远远优于现有产品,实施例1-4的产品在使用过程中没有出现任何不适。
对于本领域技术人员而言,显然本发明不限于上述示范性实施例的细节,而且在不背离本发明的精神或基本特征的情况下,能够以其他的具体形式实现本发明。因此,无论从哪一点来看,均应将实施例看作是示范性的,而且是非限制性的,本发明的范围由所附权利要求而不是上述说明限定,因此旨在将落在权利要求的等同要件的含义和范围内的所有变化囊括在本发明内。
此外,应当理解,虽然本说明书按照实施方式加以描述,但并非每个实施方式仅包含一个独立的技术方案,说明书的这种叙述方式仅仅是为清楚起见,本领域技术人员应当将说明书作为一个整体,各实施例中的技术方案也可以经适当组合,形成本领域技术人员可以理解的其他实施方式。
Claims (4)
1.一种用于偏头疼的药物,其特征在于,由以下原料按照重量份组成:葫芦素2-5份、牡荆素0.5-3份、淀粉7-15份、复合维生素3-7份、乙醇溶液5-12份、蚯蚓蛋白酶0.1-2份、硬脂酸钾1-6份、咖啡因8-18份、氨基酸3-7份和尼古丁0.1-0.5份。
2.根据权利要求1所述的用于偏头疼的药物,其特征在于,所述氨基酸为赖氨酸、谷氨酸、色氨酸、苯丙氨酸和酪氨酸的一种或者多种的混合物,复合维生素采用甲基复合维生素、微晶复合维生素和乙基复合维生素的一种或者多种的混合物。
3.根据权利要求1或2所述的用于偏头疼的药物,其特征在于,所述乙醇溶液的体积分数为40-55%,淀粉采用玉米淀粉、葛根淀粉、红薯淀粉和菱角淀粉的一种或者多种的混合物。
4.一种如权利要求1-3任一所述的用于偏头疼的药物的制备方法,其特征在于,具体步骤如下:
步骤一,将硬脂酸钾、淀粉、复合维生素和蚯蚓蛋白酶分别粉碎并且过80-120目筛子,得到硬脂酸钾粉末、淀粉粉末、复合维生素粉末和蚯蚓蛋白酶粉末备用;
步骤二,将葫芦素、牡荆素、淀粉粉末、复合维生素粉末和蚯蚓蛋白酶粉末加入乙醇溶液中,搅拌机在常温下进行搅拌,边搅拌边加入咖啡因、氨基酸和尼古丁,咖啡因、氨基酸和尼古丁加入完毕后,搅拌机在常温下以150-240rpm的转速搅拌30-60分钟,搅拌结束后将混合溶液放在55-75摄氏度的干燥箱中烘干并且烘干产物过20-30目筛,得到干燥颗粒;
步骤三,将硬脂酸钾加入到干燥颗粒中并且混合均匀,然后将混合物填充到胶囊中即可得到成品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611093827.7A CN106511984A (zh) | 2016-12-02 | 2016-12-02 | 一种用于偏头疼的药物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611093827.7A CN106511984A (zh) | 2016-12-02 | 2016-12-02 | 一种用于偏头疼的药物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106511984A true CN106511984A (zh) | 2017-03-22 |
Family
ID=58354507
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611093827.7A Withdrawn CN106511984A (zh) | 2016-12-02 | 2016-12-02 | 一种用于偏头疼的药物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106511984A (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103501609A (zh) * | 2011-01-26 | 2014-01-08 | 尼科环球有限公司 | 用于偏头痛的治疗 |
-
2016
- 2016-12-02 CN CN201611093827.7A patent/CN106511984A/zh not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103501609A (zh) * | 2011-01-26 | 2014-01-08 | 尼科环球有限公司 | 用于偏头痛的治疗 |
Non-Patent Citations (2)
Title |
---|
艾铁民: ""匍枝毛茛"", 《中国药用植物志.第3卷》 * |
金孝勤等: ""山芝麻中化学成分与抗肿瘤活性研究"", 《安徽医药》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101484587B1 (ko) | 미역귀와 멍게껍질의 혼합물 추출액을 포함하는 아토피성 피부염 개선용 조성물 | |
CN104738641A (zh) | 一种洛神花抗疲劳含片的制备方法 | |
CN105995585A (zh) | 牡丹阿胶保健食品 | |
CN107536821A (zh) | 一种盐酸达泊西汀缓释制剂 | |
WO2015027730A1 (zh) | 显著升高血清高密度脂蛋白浓度的中药复合组合物和制备方法 | |
CN106511984A (zh) | 一种用于偏头疼的药物及其制备方法 | |
CN104825835B (zh) | 一种石斛口腔溃疡含片的制备方法 | |
CN106729666A (zh) | 一种用于偏头疼的药物及其制备方法 | |
CN107753952A (zh) | 一种治疗口腔溃疡的药物组合物 | |
CN106581045A (zh) | 一种治疗偏头疼的药物及其制备方法 | |
CN106727672A (zh) | 一种治疗血管性头痛的药物及其制备方法 | |
CN106615922A (zh) | 一种降低肉鸡包涵体肝炎发病率的饲料 | |
CN101716206A (zh) | 山参颗粒及其制备方法 | |
JP2005015414A (ja) | アレルギー性疾患の症状を抑制・緩和するための薬剤または機能性食品 | |
CN105106146B (zh) | 含有中药莲子和牡蛎壳的直压片剂 | |
CN102078330A (zh) | 一种含体外培育牛黄和咖啡因的复方制剂及制备方法 | |
CN106539996A (zh) | 一种用于治疗急性发热的西药组合及其制备方法 | |
CN103652902B (zh) | 一种冬虫夏草枸杞子山药咀嚼片及制备方法 | |
CN106727621A (zh) | 一种治疗牙痛的西药散剂 | |
CN103637207B (zh) | 一种百合天门冬咀嚼片及制备方法 | |
CN103340967B (zh) | 一种治疗口疮的中药组合物及其制备方法 | |
CN105769949A (zh) | 一种用于哮喘治疗的药物组合物及其制备方法 | |
CN102217885A (zh) | 治疗神经性头痛的中药枕 | |
CN105853374A (zh) | 一种水飞蓟宾磷脂复合物的制备方法 | |
CN106860687A (zh) | 一种治疗酒精中毒及护肝的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170322 |
|
WW01 | Invention patent application withdrawn after publication |